New obesity drug and Fubo wins injunction against Disney

☕ Coffee cheers to a great trading week                                                                                                                                                                                                                                                                                                                                                                                                                 August 19, 2024 | [Read Online]( *sponsored by TradingTips GM! As usual here are today’s biggest movers. And right now we have a great special going on for [ALL our services](. Why choose one when you can have them all? Call Davis for more info (1-800-585-4488 / davis@ragingbull.com). P.S. Don’t forget to join us in [Market Masters]( to kick the week off right! FOCUS LIST🔎 RDHL - Up over 40% in the pre-market after announcing positive obesity and Diabetes results with Opaganib TNXP - Up over 30% in pre after reporting Q2 financial results and operational highlights FUBO - Up over 13% in pre after announcing it had won a preliminary Injunction Against The Walt Disney Company, FOX Corp. and Warner Bros. Discovery’s Venu Sports Joint Venture HOTLIST🔥 RDHL - Up over 40% in the pre-market after announcing positive obesity and Diabetes results with Opaganib RedHill Biopharma Ltd. (RDHL) is a specialty biopharmaceutical company that primarily focuses on gastrointestinal and infectious diseases. In the pre-market this morning, the [company announced]( positive results from multiple in vivo studies, undertaken by RedHill's partner, Apogee Biotechnology Corporation, showing the impact of opaganib[2] on weight gain and glucose tolerance in a high fat diet (HFD) model, supporting the potential clinical use of Opaganib for the prevention and therapy of Type 2 diabetes and other obesity-related disorders. The encouraging outcomes showed the benefit of opaganib therapy in suppression of HFD-induced body weight gain, loss of glucose tolerance and fat deposition. Additionally, opaganib treatment reduced weight gain and restored glucose tolerance in an already obese HFD model, suggesting its potential for treating, not just preventing, obesity-related disorders. The global obesity-diabetes drugs market is projected to be worth around $100 billion by 2034 – largely driven by Glucagon-like peptide-1 (GLP-1) inhibitors like Novo Nordisk's Ozempic and Wegovy (semaglutide) and Eli Lilly's Trulicity (dulaglutide) and Mounjaro (tirzepatide) and sodium glucose cotransporter-2 (SGLT2) inhibitors such as Boehringer Ingelheim's Jardiance (Empagliflozin). RDHL traded up over 40% in the pre-market in reaction to the news. The first target for bulls is the pre-market high at $0.4627. Beyond that, $0.5440, $0.6134 and $0.80 come into play. Below $0.4627, targets to the downside are $0.40, $0.35, and then a gap fill at $0.2901. *sponsored by TradingTips Are you ready to capitalize on the booming AI market? Our experts have identified the top 10 AI stocks set to skyrocket, including these: - Stock #4 is pushing the boundaries of reality, merging virtual & augmented worlds to create the ultimate social media experience. - Stock #7 is unlocking the secrets of data, providing unparalleled insights that are changing the game for governments & businesses alike. - Stock #10 is transforming the future of defense & national security with its cutting-edge AI solutions, safeguarding tomorrow today. [Download your FREE report now.]( *By clicking this link you agree to receive emails from TradingTips and their affiliates. You can opt out at any time. -[Privacy Policy]( TNXP - Up over 30% in pre after reporting Q2 financial results and operational highlights Tonix Pharmaceuticals Holding Corp. (TNXP) is a biopharmaceutical company that focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. In the pre-market this morning, the [company reported]( Q2 financial results and operational highlights. Highlights include: On track to submit NDA in second half 2024 for TNX-102 SL for fibromyalgia; completed successful pre-NDA meetings with FDA in second quarter 2024 FDA granted Fast Track designation for TNX-102 SL for fibromyalgia Commercial planning continues for U.S. launch of TNX-102 SL, a potential new first-line, centrally-acting, non-opioid analgesic for the management of fibromyalgia U.S. Department of Defense contract awarded for up to $34 million over 5 years to develop a broad-spectrum antiviral drug As of June 30, 2024, Tonix had $4.2 million of cash and cash equivalents, compared to $24.9 million as of December 31, 2023. Net cash used in operations was approximately $30.5 million for the six months ended June 30, 2024, compared to $56.3 million for the same period in 2023. Subsequent to the quarter ending June 30, 2024, Tonix received net proceeds of approximately $3.5 million in a securities purchase agreement with certain institutional and retail investors, and sold 0.8 million shares of common stock under the ATM Sales Agreement, for net proceeds of approximately $0.4 million. Net product revenue for the second quarter 2024 was approximately $2.2 million. The stock traded up over 30% in the pre-market in reaction to the financial results and operational update. The $0.50 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $0.55, $0.63, $0.72 and then the pre-market high at $0.75. Beyond that, $0.92, $1.10 and $1.30 come into play. Below $0.50, targets to the downside are $0.4474, and then $0.42. FUBO - Up over 13% in pre after announcing it had won a preliminary Injunction Against The Walt Disney Company, FOX Corp. and Warner Bros. Discovery’s Venu Sports Joint Venture fuboTV Inc. (FUBO) operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. Late Friday, the [company reported]( that it has been successful in stopping the launch of The Walt Disney Company, FOX Corp. and Warner Bros. Discovery’s Venu Sports joint venture (JV) after its request for a preliminary injunction was approved by the U.S. District Court, Southern District of New York today. Today’s ruling is significant as Fubo fought against three of the world’s biggest media conglomerates to create a more competitive streaming marketplace for consumers. David Gandler, co-founder and CEO, Fubo, commented: "Today’s ruling is a victory not only for Fubo but also for consumers. This decision will help ensure that consumers have access to a more competitive marketplace with multiple sports streaming options. "But our fight continues. Fubo has said all along that we seek equal treatment from these media giants, and a level playing field in our industry. Fubo had sought to stop the launch of the JV that would have controlled roughly 60%-80% of live broadcast sports content, according to its partners. Fubo presented evidence of the JV’s primary effect of limiting competition, removing consumer choice, and ultimately leading to steep price hikes for consumers and boosting profits for the partners. Fubo’s goal is to ensure a competitive sports streaming marketplace that offers consumers choice, affordable pricing, flexibility and innovation. All distributors should have the opportunity to compete in a fair market, according to Fubo. The stock traded up over 13% in the pre-market this morning after closing Friday up over 16%. The first target for bulls is the pre-market high $1.83. Beyond that, $2.13, $2.64 and $3.33 come into play. Below $1.83, targets to the downside are $1.70, $1.63, $1.50, $1.40 and then $1.30. MARKET NEWS 📰 Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at *Sponsored content: We’re a proud affiliate for Trading Tips, meaning if you click a link for a product or service, we may earn a commission at no extra cost to you. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](